Rebecca Chu, PharmD, RPh

Researchers measured autoantibody profiles of serum samples to predict patients who may develop systemic lupus erythematosus.

Researchers compared physician- and patient-reported measures of tofacitinib therapy to determine the impact of long-term treatment among patients with rheumatoid arthritis.

Researchers studied the response to pneumococcal vaccination among patients with rheumatoid arthritis receiving upadacitinib and methotrexate.

Researchers assessed whether combination therapy with methotrexate plus leflunomide was superior to methotrexate monotherapy in improving disease activity in patients with psoriatic arthritis.

Researchers assessed the prevalence of previously undiagnosed axial spondyloarthritis in patients with acute anterior uveitis and chronic back pain.

Researchers assessed physician and patient-reported effectiveness outcomes of treatment with tofacitinib vs tumor necrosis factor inhibitors, using real-world data from the Ontario Best Practices Research Initiative (OBRI).

Authors of a systematic review evaluated the literature on the link between markers of inflammation and pain in patients with knee osteoarthritis.

Researchers identified the characteristics and distribution of discoid lupus erythematosus skin lesions among Black vs non-Black patients.

Researchers evaluated the bone microarchitecture and strength in patients with primary hypertrophic osteoarthropathy using HR-pQCT.

The aim of the systematic review was to collect information currently available on health care costs associated with JIA after the introduction of biologic therapies.

A press release by the Lupus Foundation of America highlighted results from a study that determined the top barriers to lupus care and diagnosis.

Researchers reported on the final results of the RETRO trial, which was conducted to investigate the tapering and withdrawal of DMARDs in patients with RA in stable remission.

Researchers assessed the association between traditional cardiovascular risk factors and disease activity in patients with axial spondyloarthritis.

The American College of Rheumatology shows support for a decision by the Centers for Medicare and Medicaid Services to withdraw a rule implementing “Most Favored Nation” payment model for Part B drugs.

The objective of the study was to determine the risk of developing psoriatic arthritis in patients with psoriasis receiving certain treatments, such as biologics.

The objective of the study was to evaluate the trends for hospitalizations and inpatient mortality from acute myocardial infarction among patients with psoriatic arthritis.

Researchers evaluated the presence of imaging features and clinical signs of disease in healthy first-degree relatives of patients with spondyloarthritis.

Researchers assessed the risk for major adverse cardiovascular events in patients with psoriatic arthritis receiving treatment with different classes of DMARDs.

A case study of a patient who developed an acute gout flare of bilateral first metatarsophalangeal joints after initiating treatment with ibrutinib for chronic lymphocytic leukemia.

Researchers evaluated the efficacy of guselkumab in patients with psoriatic arthritis with imaging-confirmed sacroiliitis consistent with axial involvement.

Researchers evaluated the association between Assessment of Spondyloarthritis International Society Health Index (ASAS-HI) and disease activity and burden in patients with spondyloarthritis.

Researchers analyzed cardiovascular risk comorbidities among patients with rheumatoid arthritis, and the correlation between CV risk and the use of antirheumatic drugs.

Researchers aimed to study the correlation between irreversible organ damage and quality of life in systemic lupus erythematosus, and to identify the type of organ damage that is negatively correlated with QOL.